Ewart G, Bobardt M, Bentzen BH, Yan Y, Thomson A, Klumpp K, Becker S, Rosenkilde MM, Miller M, Gallay P. (2023). Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2. PLOS Pathogens. 19(8):e1011328. https://doi.org/10.1371/journal.ppat.1011328
Luscombe CA, Avihingsanon A, Supparatpinyo K, Gatechompol S, Han WM, Ewart GD, Thomson AS, Miller M, Becker S, Murphy RL (2020). Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation. The Journal of Infectious Diseases. jiaa635, https://doi.org/10.1093/infdis/jiaa635
Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J (2016). The antiviral compound BIT225 inhibits HIV‑1 replication in myeloid dendritic cells. AIDS Res Ther. 13:7
Wilkinson J, Ewart G, Luscombe C, McBride K, Ratanasuwan W, Miller M, Murphy RL (2016). A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection. J Antimicrob Chemother. 71(3):731-38
Meredith LW, Zitzmann N, McKeating JA (2013). Differential effect of p7 inhibitors on Hepatitis C virus cell-to-cell transmission. Antiviral Res. 100:636-39
Luscombe CA, Huang Z, Murray MG, Miller M, Wilkinson J, Ewart GD (2010). A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res. 86(2):144-53
Patargias G, Ewart G, Luscombe C, Fischer WB (2010). Ligand-protein docking studies of potential HIV-1 drug compounds using the algorithm FlexX. Anal Bioanal Chem. 396(7):2559-63
Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J (2010). Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother. 54(2):835-45
Wilson L, Gage P, Ewart G (2006). Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology. 353(2):294-306
Gage, P., G. Ewart, J. Melton and A. Premkumar (2005). Virus Ion Channels Formed by Vpu of HIV-1, the 6K Protein of Alphaviruses and NB of Influenza B Virus. Viral Membrane Proteins: Structure, Function and Drug Design. W. Fischer. New York, Kluwer Academic / Plenum Publishers : Chapter 15
Ewart, G.D., N. Nasr, H. Naif, G.B. Cox, A.L. Cunningham, and P.W. Gage (2004). Potential new anti-Human Immunodeficiency Virus Type 1compounds depress virus replication in cultured human macrophages. Antimicrobial Agents and Chemotherapy. 48 (6): 2325–2330
Premkumar, A., G. D. Ewart, G. B. Cox and P. W. Gage (2004). An amino-acid substitution in the influenza-B NB protein affects ion-channel gating. J Membr Biol. 197( 3): 135-43
Premkumar, A., L Wilson, G.D. Ewart, and P.W. Gage (2004). Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Letters. 557: 99-103)
Wilson, L, Mckinlay C, Gage P, Ewart,G (2004). SARS coronavirus E protein forms cation-selective ion channels. Virology. 330: 322–331
Ewart, G.D., K. Mills, G.B. Cox, and P.W. Gage (2002). Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J. 31(1): 26-35
Melton, J.V., G.D. Ewart, R.C. Weir, P.G. Board, E. Lee, and P.W. Gage (2002). Alphavirus 6K proteins form ion channels. J Biol Chem. 277(49): 46923-31
Ewart, GD., Greber, D., Cox, GB. and Gage, PW (1999). Ion Channels Formed By Vpu, An HIV-1-Encoded Protein (A Potential Target For AIDS Therapeutic Drugs?). Australian Biochemist. 30(3): 11-13
Ewart, G.D., Sutherland, T., Gage, P.W. and Cox, G.B. (1996). The Vpu protein of human immunodeficiency virus type-1 forms cation-selective ion channels. J. Virol. 70(10): 7108-7115
